Home › Cases › NSTEMI Troponin Interpretation
NSTEMI
NSTEMI Troponin Interpretation
6 questions
Question 1 · Troponin kinetics
Correct answer: Troponin is 2× the upper reference limit: repeat using this assay’s protocol and assess ECG/ischaemia before diagnosing MI
Why
Elevated troponin = myocardial injury, not automatically NSTEMI.
- Repeat using the assay-specific protocol: rise/fall suggests acute injury.
- MI also needs evidence of ischaemia and a value above the 99th-percentile upper reference limit.
- CKD/HF can cause chronic elevation; PE can cause acute injury. Do not use troponin-T cut-offs for troponin-I.
Key point
Raised troponin: repeat using the assay protocol; assess ECG/ischaemia before diagnosing MI.
Question 2 · High-sensitivity troponin algorithm
Correct answer: Rise of 8 ng/L meets the assay’s rule-in threshold: urgent ACS assessment and further sampling; not a confirmed NSTEMI diagnosis
Why
6 → 14 = +8 ng/L: rule-in pathway — urgent ACS assessment, ECG and further sampling.
- Roche Elecsys rule-in: initial ≥52 ng/L or 1 h absolute change ≥5 ng/L.
- Rule-out: initial <5 ng/L if symptoms began >3 h earlier; or initial <12 ng/L with 1 h change <3 ng/L. Otherwise observe/retest.
- Rule-in guides assessment; it does not confirm MI. Neither value yet exceeds this laboratory’s stated upper reference limit. These cut-offs are assay-specific.
Key point
Roche Elecsys: +8 ng/L in 1 h meets rule-in (≥5). Urgent ACS assessment; rule-in is not confirmed NSTEMI.
Question 3 · Causes of elevated troponin
Correct answer: Non-ischaemic troponin elevation from acute heart failure — type 2 MI or demand ischaemia is possible but decompensated HF itself causes troponin elevation
Why
Non-ischaemic causes of elevated troponin: heart failure (myocardial stretch), PE (right heart strain), myocarditis, renal failure, sepsis, tachyarrhythmia. Must always be interpreted in clinical context. Absence of chest pain does not exclude ACS. Assess serial troponin, ECG and, when indicated, imaging: HF-related myocardial injury alone is not a diagnosis of MI.
Key point
Elevated troponin ≠ always NSTEMI. HF, PE, myocarditis, AKI, sepsis all elevate troponin. Clinical context essential.
Question 4 · NSTEMI risk stratification
Correct answer: GRACE + clinical features: unstable → immediate angiography; stable high-risk → consider within 24 h; intermediate/higher NICE risk → consider within 72 h
Why
- Very high-risk (shock, refractory ischaemia): call cardiology for immediate angiography
- High-risk (e.g. GRACE >140, confirmed NSTEMI, dynamic ST/T changes): consider angiography within 24 h (ESC)
- Intermediate or higher risk (predicted 6-month mortality >3%): consider within 72 h of first admission, if no contraindications (NICE)
- Low risk: non-invasive testing; recurrent/demonstrated ischaemia → cardiology/angiography
Key point
Unstable: immediate angiography. Stable high-risk: consider within 24 h (ESC). NICE intermediate/higher risk: consider within 72 h; low risk is not an automatic 72 h cath-lab slot.
Question 5 · Type 1 vs Type 2 MI
Correct answer: Type 2 MI — demand ischaemia from haemodynamic compromise (shock + tachycardia → supply/demand mismatch). Treat the underlying cause (AF, shock)
Why
Type 1 MI: plaque rupture/erosion with thrombosis. Type 2 MI: ischaemic injury from supply/demand mismatch without acute atherothrombosis (e.g. tachyarrhythmia, anaemia, shock). Both require acute troponin rise/fall above the upper reference limit + evidence of ischaemia. Treat the AF/shock promptly; Type 2 MI does not automatically require DAPT or urgent angiography. If Type 1 ACS remains possible, seek urgent cardiology assessment.
Key point
Type 2 MI = acute injury + ischaemia from supply/demand mismatch. Treat AF/shock/anaemia; troponin elevation with tachycardia alone does not prove MI.
Question 6 · Post-NSTEMI medications
Correct answer: Aspirin 75mg + ticagrelor 90mg BD (DAPT 12 months), atorvastatin 80mg, beta-blocker, ACEi (ARB if intolerant), GTN spray PRN
Why
Post-NSTEMI discharge:
- DAPT (aspirin + ticagrelor) for 12 months (DES stents — reduces stent thrombosis)
- Atorvastatin 80mg
- Beta-blocker (especially if reduced EF)
- ACEi once haemodynamically stable, regardless of EF; ARB if ACEi-intolerant
- GTN spray PRN
- Cardiac rehab referral
- GP review 1-2 weeks post-discharge
Key point
Post-NSTEMI: DAPT 12m, atorvastatin 80mg, beta-blocker, ACEi when stable (ARB if intolerant). Cardiac rehab. GP follow-up.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.